		1110	27/1681			
' FORM D	UNITED STATES	17		V OM	IB APPROVA	
	SECURITIES AND EXCHANGE CO	MMIS	SIQN	OMB NUM		35-0076 30, 2008
	Washington, D.C. 20549		RECEIVE	Expires: Estimated a	. Aprii verage burden	
	FORM D		3	bours per re	sponse	16.00
	NOTICE OF SALE OF SECU	अधार	S 11 1 1 A A			
	PURSUANT TO REGULATION		SAUL TE	2007 SEC	USE ONLY	
		V	<u> </u>	Prefix		Serial
	SECTION 4(6) AND/OR		-300		<u>.</u>	
	UNIFORM LIMITED OFFERING E	XEM	OOMOTE	Dat	e Received	
				<u>'</u>	ı	
Name of Offering (□ check	if this is an amendment and name has changed, and indicate	e change	<u>) </u>			
Offer and sale of Class A Comm						
Filing Under (Check box(es) that	t apply): ⊠ Rule 504 □ Rule 505 □ Rule 506		Section 4(6)	ULOE		
Type of Filing: New Filing	g 🔲 Amendment					
	A. BASIC IDENTIFICATION DAT	A				
1. Enter the information request	ed about the issuer					
•	is is an amendment and name has changed, and indicate c	hange.)				
Gemin X Pharmaceuticals, Inc.	01 - 1 1 0 0 0 0 0 0 0 7 in	C- 4-X	T-lankana Nama	har (In aludina An	on Cada)	
Address of Executive Offices	(Number and Street, City, State, Zip Montreal, Quebec, H2X 2H7 Canada	Code	514-281-8989	ber (Including Ar	ea Code)	
Address of Principal Business O		Code)		ber (Including Ar	ea Code)	
(if different from Executive Office		,				
	•					
Brief Description of Business			E (110)))		11111	
B 1	25. Lancacca					
Development-stage biopharmace	utical company.			11		
			07	072369		
Type of Business Organization			_			
	☐ limited partnership, already formed		other (please speci:	îy):		
□ business trust	☐ limited partnership, to be formed					
	Month	Yea	ur			CESSI
And of an Parlimental Date (C)	0 5	0 7		☐ Estimated	•	ひにひひ
Actual or Estimated Date of Inco	orporation or Organization: Organization: (Enter two-letter U.S. Postal Service abbrevi	intion for	State:	□ Estimated		4.0 000
Jurisdiction of incorporation of (CN for Canada; FN for other foreign jurisd		Juic.	D E	JUL	1 9 2007
	51. 151 Canada, 11. 151 Cana. 1014.Bit Juniou	,		لــــا نـــــا		

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6)

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those state that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1972 (6-02) 1 of 8

A. BASIC IDENTIFICATION DATA 2. Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer. Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. □ Director ☐ General and/or Check Box(es) that Apply: □ Promoter □ Beneficial Owner Managing Partner Full Name (Last name first, if individual) Dixon, D. Michael (Number and Street, City, State, Zip Code) Business or Residence Address 3576 Park Avenue, Suite 4310, Montreal, Quebec, H2X 2H7 Canada ■ Executive Office . ix iDirector □'General and/or □ Beneficial Owner Check Box(es) that Apply: □ Promoter Managing Partner Full Name (Last name first, if individual) Shore, Gordon Business or Residence Address (Number and Street, City, State, Zip Code) 3576 Park Avenue, Suite 4310, Montreal, Quebec, H2X 2H7 Canada □ Beneficial Owner ☐ Executive Officer ☑ Director □ General and/or Check Box(es) that Apply: □ Promoter Managing Partner Full Name (Last name first, if individual) Davidson, Aaron (Number and Street, City, State, Zip Code) **Business or Residence Address** 1001 Brickell Bay Drive, 27th Floor, Miami, FL 33131 Director DI ☐ General and/or Check Box(es) that Apply: □ Promoter □ Beneficial Owner ☐ Executive Officer Managing Partner Full Name (Last name first, if individual) Roberts, Eric W. Business or Residence Address (Number and Street, City, State, Zip Code) c/o Caxton Advantage Venture Partners, L.P., 500 Park Avenue, 5th Floor, New York, NY 10022 ☐ Beneficial Owner ☐ Executive Officer ☑ Director ☐ General and/or Check Box(es) that Apply: □ Promoter Managing Partner Full Name (Last name first, if individual) Gorman, Robert (Number and Street, City, State, Zip Code) **Business or Residence Address** 10663 E. Cottontail Lane, Scottsdale, AZ 85255 ☐ Beneficial Owner ☐ Executive Officer □ Director ☐ General and/or Check Box(es) that Apply: □ Promoter Managing Partner Full Name (Last name first, if individual) Jordan, Andrew **Business or Residence Address** (Number and Street, City, State, Zip Code) 8 Swan Lane, Andover, MA 01810 Check Box(es) that Apply: □ Beneficial Owner □ Executive Officer □ Director ☐ General and/or □ Promoter Managing Partner Full Name (Last name first, if individual) Barberich, Timothy J. Business or Residence Address (Number and Street, City, State, Zip Code) 40 Elm Street, Concord, MA 01742 ☐ General and/or □ Beneficial Owner □ Executive Officer □ Director Check Box(es) that Apply: □ Promoter **Managing Partner** Full Name (Last name first, if individual)

(Number and Street, City, State, Zip Code)

c/o Sanderling Venture LLP, 400 South El Camino Drive, Suite 1200, San Mateo, CA 94402-1708

McNeil, Robert G.

Business or Residence Address

- ,				B. INFO	ORMATIO	N ABOUT	OFFERI	₹G				
1. Has the iss	nor sold or	does the is	sues intend	to call to r	on accredit	ed investor	e in this off	Terina?	· · · · · · · · · · · · · · · · · · ·			No D
1. Has the iss	uer soia, oi	does me is								•••••		_
			Ansv	ver also in	Appendix, (Column 2,	if filing und	ler ULOE.				
2. What is the	e minimum	investment	that will b	e accepted	from any in	dividual?					\$	
* Subject to the	ne discretio	n of the Issi	uer.									No
3. Does the o	ffering pen	nit joint ow	nership of	a single uni	t?			********				
4. Enter the in remuneration agent of a bro persons to be Full Name (La	for solicita ker or deal listed are a	tion of purc er registered ssociated pe	hasers in co I with the S ersons of su	nnection v EC and/or	vith sales of with a state	securities or states, li	in the offeri ist the name	ng. If a per of the brol	rson to be li cer or deale	isted is an r. If more	associated than five	i person or
Not applicable	e											
Business or R		ddress (Nu	mber and S	treet, City,	State, Zip C	Code)					-	
Name of Asso	ciated Bro	ker or Deale	er	- "-					 , _			
States in White					Solicit Purc							All States
[AL]	All State 0	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	(HI)	[ID]
[IL]	[IN]	[lA]	[KS]	[KY]	[LA]	(ME)	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	{VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]
Full Name (La				_ 	`							
Not applicable	•											
Business or R		ddress (Nu	mber and S	treet, City,	State, Zip C	Code)	-					
Name of Asso	ociated Bro	ker or Deale	er									_
States in Whi					Solicit Purc	hasers						
•		r check ind						IDOI	(121.1			All States
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	(FL)	[GA]	[HI]	[ID]
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME] [NY]	[MD] [NC]	[MA] [ND]	[MI] [OH]	[MN] [OK]	[MS] [OR]	[MO] [PA]
[MT]	[NE] [SC]	[NV] [SD]	[NH]	[NJ]	[NM]	[VT]	[VA]	[WA]	[WV]	[WI]	[UK] [WY]	[PR]
[RI] Full Name (L			(TN)	[TX]	[UT]	[VI]	[tv]	[47]	[** *]	[171]	[**1)	[1 [7]
		ist, it mare	, addi, j									
Not applicabl Business or R		ddees (Niu	mber and S	treet City	State 7 in C	ode)						
Dusiness of K	esidence A	uui eesiuui	moei and 3	ireei, City,	State, Zip C	.ouc)						
Name of Asso	ciated Bro	ker or Deal	ег	-								
States in Whi					Solicit Purc						. m.	All States
[AL]	All State ([AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	(HI)	[ID]
[IL]	[IN]	(, [IA]	[KS]	[KY]	(LA)	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.				
	Type of Security		egate ing Price	Amo	unt Already Sold
	Debt	\$	0	\$_	_ 0
	Equity	\$ <u>211</u>	,531	\$2	11.531
	☑ Common ☐ Preferred				
	Convertible Securities (including warrants)	s_ _	0	\$_	0
	Partnership Interests	S	0	\$_	0
	Other (Specify)	\$	0	\$_	0
	Total		1.531	\$2	11,531
	Answer also in Appendix, Column 3, if filing under ULOE.				
	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."		umber vestors		Aggregate ollar Amoun of Purchases
	Accredited Investors		0	S.	0
	Non-accredited Investors		14	\$ <u>2</u>	211,531
	Table (for filling and to Bull fill and a		1.4	•	111 521
	Total (for filings under Rule 504 only)		14	პ ፈ	211,531
3.	Answer also in Appendix, Column 4, if filing under ULOE. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities				
	sold by the issuer, to date, in offerings of the types indicated, the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.				
	Type of offering		pe of	D	ollar Amoun
	Rule 505		curity A	S	Sold N/A
	Regulation A		/A	_	N/A
	Rule 504		uity		211,531
	Total		uity		211,531
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.				
	Transfer Agent's Fees		(⊐ \$ _	0
	Printing and Engraving Costs		[\$ _	0
	Legal Fees				5,000
	Accounting Fees			⊐ \$.	0
	Engineering Fees		(ב ג ַ	0
	Sales Commissions (specify finders' fees separately)		(_ \$_	_0
	Other Expenses (identify)			⊐ \$_	0
	Total			⊗ \$ <u>:</u>	5,000

C. OFFERING PRICE	NUMBER OF INVESTORS, EXPENSES AND USE	OF P	ROCEEDS	
1 and total expenses furnished in response	e offering price given in response to Part C - Question to Part C - Question 4.a. This difference is the			\$206,531
used for each of the purposes shown. If the estimate and check the box to the left of the	ross proceeds to the issuer used or proposed to be amount for any purpose is not known, furnish an estimate. The total of the payments listed must equal forth in response to Part C - Question 4.b above.			
the adjusted gross proceeds to the issues see	total in response to 1 art C = Question 4.0 accord.		Payments to Officers, Directors, & Affiliates	k Payments To Others
Salaries and fees			\$0	□ \$ <u>0</u>
			\$0	s 0
Purchase, rental or leasing and installation	on of machinery and equipment		<u> </u>	□ \$ <u> </u>
	gs and facilities		\$ <u>0</u>	□ \$ <u>0</u>
Acquisition of other businesses (including offering that may be used in exchange for	ng the value of securities involved in this		s 0	- \$ <u>0</u>
			s 0	
		_		≥ \$ 206,531
				□ \$ _0
Ollier (specify).				_
			\$ <u>0</u>	- \$ 0
			\$ 0	
Total Payments Listed (Column totals a	dded)		⊠ \$	206,531
	D. FEDERAL SIGNATURE		<u></u>	<u> </u>
			· Elad undar D	who SOS the
following signature constitutes an undertaki	aned by the undersigned duly authorized person. If this n ng by the issuer to furnish to the U.S. Securities and Exc issuer to any non-accredited investor pursuant to paragra	hange	Commission, (upon written request
Issuer (Print or Type)	Signature		Date	-
Gemin X Pharmaceuticals, Inc.	Dury		لسلا	y 11 2007
Name of Signer (Print or Type)	Title of Signer (Print or Type)		 	
D. Michael Dixon	Chief Financial Officer			

- ATTENTION -

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

